BioMarin Pharmaceuticals BMRN Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's debt issuance cost amortization?
- BioMarin Pharmaceuticals (BMRN) reported debt issuance cost amortization of $6.09M in Q1 2026.
- How has BioMarin Pharmaceuticals's debt issuance cost amortization changed year-over-year?
- BioMarin Pharmaceuticals's debt issuance cost amortization increased by 822.1% year-over-year, from $660K to $6.09M.
- What is the long-term trend for BioMarin Pharmaceuticals's debt issuance cost amortization?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's debt issuance cost amortization has grown at a -10.8% compound annual growth rate (CAGR), from $4.15M to $2.62M.
- What does debt issuance cost amortization mean?
- The non-cash portion of costs related to raising debt capital.
- How do you interpret debt issuance cost amortization?
- Consistent levels suggest stable debt management, while spikes may indicate recent refinancing activities.
- How does debt issuance cost amortization compare across companies?
- Standard for companies with significant long-term debt obligations.